Physician profile
Ronald Mark Short
NPI 1205823473
$2,631.86
in general payments reported to CMS, 2019-2025
28 companies · $1,216 in 2025
The $1,216 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.89 · 2021: $117 · 2022: $71.43 · 2023: $386 · 2024: $786 · 2025: $1,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,387.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $894.53 | 2021-2025 | Rinvoq, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $229.46 | 2022-2025 | Entyvio |
| Janssen Biotech, INC. | $207.10 | 2019-2025 | Tremfya, Stelara |
| Aimmune Therapeutics, INC. | $130.91 | 2024-2025 | Vowst, Zenpep |
| Laborie Medical Technologies Corp. | $120.13 | 2025 | |
| Ardelyx, INC. | $104.89 | 2024-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $104.73 | 2023 | Zeposia |
| Pfizer INC. | $104.16 | 2023-2025 | |
| Braintree Laboratories, INC. | $90.08 | 2023-2025 | Suflave, Sutab |
| Qol Medical, LLC | $86.50 | 2024-2025 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $85.22 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.92 | 2024-2025 | Xifaxan |
| Mallinckrodt Hospital Products INC. | $50.52 | 2024 | Terlivaz |
| Intercept Pharmaceuticals, INC. | $37.38 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $36.32 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $33.94 | 2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $33.76 | 2025 | Dupixent |
| Lilly USA, LLC | $32.76 | 2024 | Omvoh |
| Allergan, INC. | $26.32 | 2019 | |
| Novo Nordisk INC | $24.59 | 2025 | Wegovy |
| Boston Scientific Corporation | $21.87 | 2023 | |
| Celltrion USA INC. | $20.87 | 2025 | Vegzelma |
| Genzyme Corporation | $18.72 | 2024 | |
| Capsovision, INC. | $18.32 | 2024 | Capsocam Plus |
| Celgene Corporation | $16.16 | 2021 | |
| Lucid Diagnostics INC. | $16.13 | 2023 | |
| Organon LLC | $15.34 | 2024 | |
| Evoke Pharma, INC. | $14.23 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Short listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.